Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation.
Existing immunosuppressive therapies used for solid-organ transplantation have narrow therapeutic indices, whereby underdosing is associated with acute immunological rejection of the transplanted organ and overdosing is associated with infections and malignancy, as well as organ-specific toxicities. There is significant inter-individual variation in the pharmacokinetics and pharmacodynamics of these drugs, an issue that has been addressed, in part, by therapeutic drug monitoring. Genetic polymorphisms in drug metabolising enzymes, drug efflux pumps and drug targets which may underly this heterogeneity have been identified and may provide a tool to guide prescribing. There are a number of associations between genotype and pharmacology, but as of now, only thiopurine-S-methyltransferase and cytochrome P450 3A5 have a sufficiently large influence to have potential in guiding therapy. Recent studies have also identified that donor genotype may play a significant role in immunosuppressive drug pharmacokinetics and pharmacodynamics.
Ng
Fu Liang
FL
Cellular and Molecular Medicine: Renal Medicine and Cardiac and Vascular Sciences Analytical Unit, St. George's, University of London, Cranmer Terrace, London, UK.
Holt
David W
DW
MacPhee
Iain A M
IA
D000818:Animals; D006084:Graft Rejection / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology; D006801:Humans; D016377:Organ Transplantation / Q000379:methods / Q000639:trends; D010597:Pharmacogenetics / Q000379:methods* / Q000639:trends; D019737:Transplants